MAPT and Mental deterioration: However, the longitudinal course of these concerns about cognitive decline remains unclear, particularly with regard to their relationships with brain-based AD biomarkers (i.e., cerebral amyloid and tau protein burden) in the preclinical or prodromal stages of disease.